Back to top

biotechnology: Archive

Zacks Equity Research

Clovis (CLVS) Plummets on News of Possible Bankruptcy Filing

Clovis (CLVS) tanks following the possibility of a bankruptcy filing in the near term after recent regulatory developments impacted current revenues and the commercial potential of Rubraca.

PFENegative Net Change CLVSPositive Net Change PBYIPositive Net Change SNDXPositive Net Change

Zacks Equity Research

Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on Update

Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week.

REGNNegative Net Change AMGNNegative Net Change MRNANegative Net Change

Zacks Equity Research

Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion

Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemotherapy, irrespective of PD-L1 expression levels.

REGNNegative Net Change SNYPositive Net Change DVAXPositive Net Change PBYIPositive Net Change

Zacks Equity Research

bluebird (BLUE) Q3 Earnings Top, Revenues Miss Estimates

While the commercial launch of Zynteglo is underway, bluebird's (BLUE) Q3 losses narrow but revenues miss estimates.

DVAXPositive Net Change PBYIPositive Net Change

Zacks Equity Research

Denali (DNLI) Lags Q3 Earnings Estimates, Pipeline in Focus

Denali (DNLI) posts a wider Q3 loss. Collaboration revenues decline year over year.

SNYPositive Net Change BIIBPositive Net Change DNLINegative Net Change

Zacks Equity Research

Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y

Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.

RHHBYPositive Net Change BMYPositive Net Change NVOPositive Net Change PRTAPositive Net Change